Silence Therapeutics plc Share Price
Stocks
SLN
US82686Q1013
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe BZX
11:27:34 14/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 13.72 USD | -1.83% |
|
+14.73% | +125.49% |
| 13/08 | European Equities Traded in the US Rise in Thursday Trading | MT |
| 12/08 | UK's Silence Therapeutics Prices $175 Million Offering in US | MT |
| Market Cap | 62Cr 84Cr 73Cr 69Cr 117.16Cr 8.07TCr 119.1Cr 802.9Cr 313.92Cr 4.04TCr 316.99Cr 310.11Cr 13TCr | P/E 2026 * |
-12.8x | P/E 2027 * | -16.6x |
|---|---|---|---|---|---|
| Enterprise Value | 49Cr 66Cr 57Cr 54Cr 92Cr 6.35TCr 94Cr 631.42Cr 246.88Cr 3.18TCr 249.29Cr 243.88Cr 11TCr | EV / Sales 2026 * |
1,487x | EV / Sales 2027 * | 116x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| 1 day | -1.83% | ||
| 1 week | +14.73% | ||
| Current month | +30.70% | ||
| 1 month | +40.62% | ||
| 3 months | +92.29% | ||
| 6 months | +173.65% | ||
| Current year | +125.49% |
| 1 week | 13.36 |  | 17.58 |
| 1 month | 9.57 | | 17.58 |
| Current year | 4.19 | | 17.58 |
| 1 year | 4.19 | | 17.58 |
| 3 years | 1.97 | | 27.72 |
| 5 years | 1.97 | | 27.72 |
| 10 years | 1.97 | | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 01/12/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 01/02/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 21/06/2018 |
Iain Ross
CHM | Chairman | 72 | 01/01/2004 |
Tim McInerney
BRD | Director/Board Member | 65 | 05/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06/07/26 | Sell | 8,65,112 | 0.6105% | |||
| 02/01/26 | Free | Chief Financial Officer | 3,75,000 | 0.2646% | ||
| 02/01/26 | Free | Director | 90,000 | 0.0635% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83% | +14.73% | +143.52% | +124.39% | 84Cr | |
| -1.78% | -1.68% | +1.99% | +13.84% | 4.92TCr | |
| +0.38% | -1.27% | +462.30% | +575.13% | 4.33TCr | |
| -2.61% | -0.50% | +11.90% | +69.76% | 4.05TCr | |
| -1.73% | -0.56% | +25.32% | +7.83% | 3.98TCr | |
| -0.50% | +3.08% | +19.91% | +47.26% | 3.27TCr | |
| +0.27% | -3.04% | - | - | 1.62TCr | |
| -0.53% | -2.01% | +26.19% | +117.89% | 1.62TCr | |
| +0.49% | +0.92% | +4.32% | +22.16% | 1.4TCr | |
| -0.97% | +3.84% | +78.27% | +28.05% | 1.34TCr | |
| Average | -0.90% | +3.85% | +85.97% | +111.81% | 2.66TCr | |
| Weighted average by Cap. | -1.06% | +2.60% | +95.65% | +131.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 4L 4L 4L 6L 4.27Cr 6L 42.46L 16.6L 2.14Cr 16.76L 16.4L 7.1Cr | 38.82L 52.59L 45.42L 42.68L 72.98L 50Cr 74.18L 5Cr 1.96Cr 25Cr 1.97Cr 1.93Cr 84Cr |
| Net income | -4.02Cr -5.45Cr -4.71Cr -4.43Cr -7.57Cr -521.43Cr -7.69Cr -52Cr -20Cr -261.12Cr -20Cr -20Cr -867.72Cr | -8.31Cr -11Cr -9.72Cr -9.13Cr -16Cr -1.08TCr -16Cr -107.03Cr -42Cr -538.93Cr -42Cr -41Cr -1.79TCr |
| Net Debt | -13Cr -18Cr -16Cr -15Cr -25Cr -1.72TCr -25Cr -171.47Cr -67Cr -863.43Cr -68Cr -66Cr -2.87TCr | -17Cr -24Cr -20Cr -19Cr -33Cr -2.25TCr -33Cr -224.23Cr -88Cr -1.13TCr -89Cr -87Cr -3.75TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | $13.71 | -1.86% | 4,49,934 |
| 13/26/13 | $13.97 | +2.87% | 28,14,361 |
| 12/26/12 | $13.58 | -7.74% | 54,43,587 |
| 11/26/11 | $14.72 | -4.60% | 32,89,354 |
| 10/26/10 | $15.43 | +29.12% | 1,62,08,741 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SLN Stock
Select your edition
All financial news and data tailored to specific country editions
